NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Fortitech, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Technical and R&D Investments Reinforce Fortitech Europe's Growth Objectives - Halfway through 2006, Fortitech Europe continues to take significant strides toward optimizing its ability to supply food and beverage manufacturers a full range of top-quality nutrient premixes
Technical and R&D Investments Reinforce Fortitech Europe's Growth Objectives

 

NewswireTODAY - /newswire/ - Schenectady, NY, United States, 2006/05/22 - Halfway through 2006, Fortitech Europe continues to take significant strides toward optimizing its ability to supply food and beverage manufacturers a full range of top-quality nutrient premixes .

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In the past few weeks, Fortitech Europe has begun a brand new production line for oil-soluble nutrient premixes. The company invested heavily in new custom-made equipment and machinery in order to meet specifications for the manufacture of oily premixes. This highly-proprietary production line is based on well-known, documented technology from Fortitech’s headquarter facility based in the United States. This new oily premix capability allows Fortitech Europe to provide customers the benefits of having a top-quality manufacturer offering both water and oil soluble nutrient systems to the food, beverage and pharmaceutical industries.

Fortitech Europe has also increased its technical R&D capacity by employing an additional formulation chemist, Rikke Frandsen. Frandsen joins Fortitech Europe with a strong technical background in the food and beverage industry from working as a research scientist with ingredient producer Chr. Hansen A/S.

The above developments support Fortitech Europe’s ongoing commitment of remaining a leading global supplier of nutrient premixes while at the same time being present at the local level to work with and supply European, African and Middle Eastern customers. Fortitech Europe’s recent Halal certification also supports this ongoing global excellence and service initiative.

About Fortitech Europe ApS

Fortitech Europe ApS (fortitech.com) is part of the global network of manufacturing and distribution companies of Fortitech, Inc., the world leader in the development of custom nutrient premixes for the food, drink and pharmaceutical industries. Located in Gadstrup, Denmark, the company is exclusively dedicated to the manufacture of nutrient premixes. Fortitech Europe is ISO 9001:2000 certified and meets kosher and Halal requirements. The company also meets HACCP and allergen monitoring program standards. FortiSource™ - the ultimate fortification destination. Not just premixes...Strategic Nutrition.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Fortitech, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Technical and R&D Investments Reinforce Fortitech Europe's Growth Objectives

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mark Fanion - Fortitech.com 
518-372-5155 info[.]fortitech.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Fortitech, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Fortitech, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery
Bylvay® (odevixibat) Data Shows Sustained Improvement in Severe Itch and Serum Bile Acid Levels in Patients with PFIC and ALGS
Genome BC, STEMCELL Technologies and UBC Partner to Accelerate the Ability to Develop Stem Cells
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with its Microarray Detection Platform
BASF Partners with Acies Bio to Drive Sustainable Production of Personal and Home Care Ingredients
Ipsen’s Kayfanda® (odevixibat) Approved in European Union for Cholestatic Pruritus in Alagille Syndrome, A Rare Liver Disease
STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)